On April 6, 2022 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate in three upcoming investor conferences (Press release, Enveric Biosciences, APR 6, 2022, View Source [SID1234611512]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Benzinga Psychedelics Capital Conference
Date: Tuesday, April 19th at 11:10 a.m. ET
Location: Fontainebleau Miami Beach in Miami, FL
To attend, please register here.
Sequire Cannabis & Psychedelic Conference
Date: Wednesday, April 20th at 1:00 p.m. ET
Location: Virtual
To attend, please register here.
KCSA Psychedelics Investor Conference
Date: Wednesday, April 27th at 11:00 a.m. ET
Location: Virtual
To attend, please register here.
For more information about the conferences, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate representative, or send an email to KCSA Strategic Communications at [email protected].